Literature DB >> 26194276

DPP4 in anti-tumor immunity: going beyond the enzyme.

Kei Ohnuma1, Ryo Hatano1, Chikao Morimoto1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26194276     DOI： 10.1038/ni.3210

Source DB:  PubMed          Journal:  Nat Immunol        ISSN： 1529-2908            Impact factor:   25.606


× No keyword cloud information.
  12 in total

Review 1.  Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function.

Authors:  Kei Ohnuma; Nam H Dang; Chikao Morimoto
Journal:  Trends Immunol       Date:  2008-05-02       Impact factor: 16.687

2.  CD26-mediated induction of EGR2 and IL-10 as potential regulatory mechanism for CD26 costimulatory pathway.

Authors:  Ryo Hatano; Kei Ohnuma; Haruna Otsuka; Eriko Komiya; Izumi Taki; Satoshi Iwata; Nam H Dang; Ko Okumura; Chikao Morimoto
Journal:  J Immunol       Date:  2014-12-29       Impact factor: 5.422

3.  CXCR3 in T cell function.

Authors:  Joanna R Groom; Andrew D Luster
Journal:  Exp Cell Res       Date:  2011-03-10       Impact factor: 3.905

Review 4.  CD26 a cancer stem cell marker and therapeutic target.

Authors:  Samuel Davies; Aline Beckenkamp; Andréia Buffon
Journal:  Biomed Pharmacother       Date:  2015-03-04       Impact factor: 6.529

5.  Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy.

Authors:  Rosa Barreira da Silva; Melissa E Laird; Nader Yatim; Laurence Fiette; Molly A Ingersoll; Matthew L Albert
Journal:  Nat Immunol       Date:  2015-06-15       Impact factor: 25.606

Review 6.  Clinical blockade of PD1 and LAG3--potential mechanisms of action.

Authors:  Linh T Nguyen; Pamela S Ohashi
Journal:  Nat Rev Immunol       Date:  2015-01       Impact factor: 53.106

Review 7.  The role of CD26/dipeptidyl peptidase IV in cancer.

Authors:  Pamela A Havre; Masako Abe; Yasuyo Urasaki; Kei Ohnuma; Chikao Morimoto; Nam H Dang
Journal:  Front Biosci       Date:  2008-01-01

8.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

9.  Human CD8+CXCR3+ T cells have the same function as murine CD8+CD122+ Treg.

Authors:  Zhe Shi; Yusuke Okuno; Muhaimin Rifa'i; Agustina Tri Endharti; Kazuyuki Akane; Ken-Ichi Isobe; Haruhiko Suzuki
Journal:  Eur J Immunol       Date:  2009-08       Impact factor: 5.532

10.  The emerging role of CXCL10 in cancer (Review).

Authors:  Mingli Liu; Shanchun Guo; Jonathan K Stiles
Journal:  Oncol Lett       Date:  2011-05-09       Impact factor: 2.967
View more
  9 in total

1.  A multi-center retrospective analysis of the effect of DPP4 inhibitors on progression-free survival in advanced airway and colorectal cancers.

Authors:  Azka Ali; Alejandra Fuentes; William Paul Skelton; Yu Wang; Susan McGorray; Chintan Shah; Rohit Bishnoi; Long H Dang; Nam H Dang
Journal:  Mol Clin Oncol       Date:  2018-11-13

2.  Molecular design of near-infrared (NIR) fluorescent probes targeting exopeptidase and application for detection of dipeptidyl peptidase 4 (DPP-4) activity.

Authors:  Yuki Hoshino; Kenjiro Hanaoka; Kei Sakamoto; Masahiro Yasunaga; Takashi Kojima; Daisuke Kotani; Ayumu Nomoto; Eita Sasaki; Toru Komatsu; Tasuku Ueno; Hiroyuki Takamaru; Yutaka Saito; Yasuyuki Seto; Yasuteru Urano
Journal:  RSC Chem Biol       Date:  2022-03-24

3.  First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.

Authors:  Eric Angevin; Nicolas Isambert; Véronique Trillet-Lenoir; Benoit You; Jérôme Alexandre; Gérard Zalcman; Philippe Vielh; Françoise Farace; Fanny Valleix; Thomas Podoll; Yu Kuramochi; Itaru Miyashita; Osamu Hosono; Nam H Dang; Kei Ohnuma; Taketo Yamada; Yutaro Kaneko; Chikao Morimoto
Journal:  Br J Cancer       Date:  2017-03-14       Impact factor: 7.640

4.  DPPIV promotes endometrial carcinoma cell proliferation, invasion and tumorigenesis.

Authors:  Xiaoqing Yang; Xinhua Zhang; Rongrong Wu; Qicheng Huang; Yao Jiang; Jianbing Qin; Feng Yao; Guohua Jin; Yuquan Zhang
Journal:  Oncotarget       Date:  2017-01-31

5.  Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody.

Authors:  Yutaro Kaneko; Ryo Hatano; Naoto Hirota; Nicolas Isambert; Véronique Trillet-Lenoir; Benoit You; Jérôme Alexandre; Gérard Zalcman; Fanny Valleix; Thomas Podoll; Yoshimi Umezawa; Seiichi Takao; Satoshi Iwata; Osamu Hosono; Tetsuo Taguchi; Taketo Yamada; Nam H Dang; Kei Ohnuma; Eric Angevin; Chikao Morimoto
Journal:  Biomark Res       Date:  2021-03-23

6.  Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma.

Authors:  Kazuhiko Nakagawa; Takashi Kijima; Morihito Okada; Masahiro Morise; Motoyasu Kato; Katsuya Hirano; Nobukazu Fujimoto; Mitsuhiro Takenoyama; Hiroshi Yokouchi; Yuichiro Ohe; Toyoaki Hida; Keisuke Aoe; Takumi Kishimoto; Masato Hirokawa; Hironori Matsuki; Yutaro Kaneko; Taketo Yamada; Chikao Morimoto; Masayuki Takeda
Journal:  JTO Clin Res Rep       Date:  2021-04-29

7.  Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent.

Authors:  Bassam M Ayoub; Shereen Mowaka; Marwa M Safar; Nermeen Ashoush; Mona G Arafa; Haidy E Michel; Mariam M Tadros; Mohamed M Elmazar; Shaker A Mousa
Journal:  Sci Rep       Date:  2018-06-12       Impact factor: 4.379

8.  Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development.

Authors:  Carlos R Figueiredo; Helen Kalirai; Joseph J Sacco; Ricardo A Azevedo; Andrew Duckworth; Joseph R Slupsky; Judy M Coulson; Sarah E Coupland
Journal:  J Pathol       Date:  2020-04       Impact factor: 7.996

9.  Differentially expressed serum proteins in children with or without asthma as determined using isobaric tags for relative and absolute quantitation proteomics.

Authors:  Ming Li; Mingzhu Wu; Ying Qin; Huaqing Liu; Chengcheng Tu; Bing Shen; Xiaohong Xu; Hongbo Chen
Journal:  PeerJ       Date:  2020-11-03       Impact factor: 2.984
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.